Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Related to this article

FDA approves GSK’s bepirovirsen for hepatitis B, putting antisense oligonucleotide scale-up in focus.

October 21st, 2026

FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note

FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.

October 21st, 2026

AAPS PharmSci 360 2026: E&L Standards Harmonization

Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.

October 21st, 2026

PharmTech AI Pulse Check: New Approach Methodologies Demand New QC Skills

Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.

Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.

October 21st, 2026

Nitrosamine Problems and Industry Solutions: PharmTech Explained

Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.

OpenAI acquires Orchestra Bio, adding AI agents for drug program coordination to its Rosalind suite.

October 20th, 2026

OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio

OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.

October 20th, 2026

AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing

Ravi Kiran Kaja, PhD, explains how USP’s industry-wide initiative aims to build confidence in trace-level extractables and leachables results.

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS) | © Tada Images - stock.adobe.com (521699065)

October 20th, 2026

Drug-Device Combination Apps: The FDA's 3 Questions for Sponsors

FDA final guidance defines when companion app output counts as drug labeling and when device-connected or standalone apps belong in prescribing information.

Recyclable blisters, EU PPWR rules, and digital patient leaflets are reshaping drug packaging today.

October 20th, 2026

Sustainability in Healthcare Packaging: The Journey From Yesterday to Tomorrow

Science, circularity, regulation, and technology are reshaping how the industry develops packaging for medicines.

Focus on freeze drying digital supplement

Articles in this issue

Related to this article

Trending on Pharmaceutical Technology

FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note

OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio

Nitrosamine Problems and Industry Solutions: PharmTech Explained

Sustainability in Healthcare Packaging: The Journey From Yesterday to Tomorrow

Germany’s Medical Biotechnology Sector is Flourishing